Home›The Library›Semaglutide
Semaglutide
Yes, it works, and yes it's a real approved drug — sold under three different brand names for three different regulatory purposes. But "semaglutide" bought outside a licensed pharmacy on a valid prescription is a different legal situation entirely, and that channel is being formally closed.
In brief
Should you care? Yes — this is one of the most searched peptide names there is, and most of that search traffic is about the compounded, non-pharmacy version, not the approved drug the trials were actually run on.The short version
- Real drug, real trials. Multiple large, controlled human trials back it, for more than one indication.
- Three brand names, three purposes: Ozempic (type 2 diabetes), Wegovy (chronic weight management), Rybelsus (oral, diabetes).
- The compounded pathway is closing. FDA has proposed excluding it from the list that let outsourcing pharmacies compound it during the shortage.
What it is
Semaglutide is a GLP-1 receptor agonist — a once-weekly injectable (or once-daily oral) analog of human glucagon-like peptide-1, developed by Novo Nordisk. It slows gastric emptying and increases satiety, which is the basis for both its diabetes and its weight-management effects.
What the trial evidence shows
SUSTAIN-6 (Marso et al., N Engl J Med 2016, DOI 10.1056/NEJMoa1607141) found a 26% reduction in the composite of nonfatal heart attack, nonfatal stroke and cardiovascular death in high-cardiovascular-risk type 2 diabetes patients — the basis for a 2020 label expansion for cardiovascular risk reduction. STEP 1 (Wilding et al., N Engl J Med 2021, DOI 10.1056/NEJMoa2032183, PMID 33567185) — 1,961 adults without diabetes, 68 weeks — found mean weight loss of 14.9% on 2.4mg semaglutide versus 2.4% on placebo, the pivotal trial behind Wegovy's 2021 obesity approval. Rybelsus (oral) was approved in 2019 as the first oral GLP-1 medicine.
The compounded/grey-market version
During the 2022–2024 shortage, FDA allowed licensed compounding pharmacies to prepare semaglutide from bulk substance under sections 503A/503B. The shortage was declared resolved in February 2025. On 30 April 2026, FDA proposed excluding semaglutide — along with tirzepatide and liraglutide — from the 503B bulks list entirely, finding no sufficient clinical need once the shortage ended (Federal Register 2026-08552; FDA press release, 30 Apr 2026). The comment period was later extended to 30 July 2026. If finalized, this closes the compounding pathway's legal basis, not just its shortage-era justification.
Not the same as the branded pen
"Semaglutide" sold by online peptide vendors as a vial, outside a pharmacy dispensing an actual prescription, sits outside the approved-drug framework regardless of purity claims. See why RUO labelling doesn't change this.
Safety notes
The label carries a boxed warning for thyroid C-cell tumor risk, based on rodent carcinogenicity studies — this has not been established in humans, and the drug is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN2. Gastrointestinal side effects (nausea, vomiting) are common and are the most frequent reason people stop taking it. In SUSTAIN-6, a retinopathy complication signal appeared specifically in patients with pre-existing diabetic retinopathy — worth knowing if that applies to you, not a general population risk.
References
- Marso et al., "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes," N Engl J Med 2016;375:1834-1844, DOI 10.1056/NEJMoa1607141.
- Wilding et al., "Once-Weekly Semaglutide in Adults with Overweight or Obesity," N Engl J Med 2021;384:989-1002, DOI 10.1056/NEJMoa2032183, PMID 33567185.
- FDA, "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List," press release, 30 April 2026; Federal Register 2026-08552 (1 May 2026), comment period extended per Federal Register 2026-12937 (26 June 2026).